ATHENA (GOG-3020/ENGOT-ov45): A randomised, double-blind, placebo-controlled phase III study of the poly (ADP-ribose) polymerase (PARP) inhibitor rucaparib 1 the PD-1 inhibitor nivolumab following frontline platinum-based chemotherapy in ovarian cancer

被引：0
|
作者：
Fujiwara, K. [1 ]
Chou, H-H. [2 ]
Kim, J-W. [3 ]
Tan, D. S. [4 ]
Tamura, K. [5 ]
Katsumata, N. [6 ]
Harano, K. [7 ]
Hasegawa, K. [1 ]
Hume, S. [8 ]
Jones, E. [9 ]
Goble, S. [10 ]
Sullivan, L. [11 ]
Shih, D. [12 ]
Coleman, R. L. [13 ]
McNeish, I. [14 ]
Monk, B. [15 ]
Kristeleit, R. [16 ]
机构：
[1] Saitama Med Univ, Int Med Ctr, Gynecol Oncol, Saitama, Japan
[2] Chang Gung Mem Hosp, Obstet & Gynecol, Taoyuan, Taiwan
[3] Seoul Natl Univ, Coll Med, Obstet & Gynecol, Seoul, South Korea
[4] Natl Univ Canc Inst, Haematol Oncol, Singapore, Singapore
[5] NCCH, Breast & Med Oncol, Tokyo, Japan
[6] Nippon Med Sch, Musashi Kosugi Hosp, Med Oncol, Kawasaki, Kanagawa, Japan
[7] Natl Canc Ctr Hosp East NCCE, Dev Therapeut Breast Med Oncol, Kashiwa, Chiba, Japan
[8] Clovis Oncol Inc, Clin Sci, Boulder, CO USA
[9] Clovis Oncol Inc, Clin Res, Boulder, CO USA
[10] Clovis Oncol Inc, Biostat, Boulder, CO USA
[11] Clovis Oncol Inc, Clin Sci, Boulder, CO USA
[12] Clovis Oncol Inc, Clin Operat, Boulder, CO USA
[13] Univ Texas MD Anderson Canc Ctr, Gynecol Oncol & Reprod Med, Houston, TX 77030 USA
[14] Imperial Coll London, Surg & Canc, London, England
[15] Creighton Univ, Univ Arizona, Sch Med, Coll Med,Arizona Oncol US Oncol Network,Gynecol O, Phoenix, AZ USA
[16] UCL, Canc Inst, Oncol, London, England
来源：
ANNALS OF ONCOLOGY | 2019年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
263TiP
引用
收藏
页数：2
相关论文
共 8 条
  • [1] ATHENA (GOG-3020/ENGOT-OV45; EUDRACT 2017-004557-17; NCT03522246): A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY OF THE POLY(ADP-RIBOSE) POLYMERASE (PARP) INHIBITOR RUCAPARIB + THE PD-1 INHIBITOR NIVOLUMAB FOLLOWING FRONTLINE PLATINUM-BASED CHEMOTHERAPY IN OVARIAN CANCER (OC)
    Christopoulou, A.
    Marme, F.
    Oaknin, A.
    Lorusso, D.
    Safra, T.
    Lindahl, G.
    Chudecka-Glaz, A.
    Ciuleanu, T.
    Collins, D. C.
    Demirkiran, F.
    Lifrenko, I.
    Van Gorp, T.
    Coleman, R. L.
    Fujiwara, K.
    Oza, A. M.
    Westin, S. N.
    O'Malley, D. M.
    Herzog, T. J.
    Eskander, R.
    Wilson, M.
    Argire, S.
    Grechko, N.
    McNeish, I. A.
    Monk, B. J.
    Kristeleit, R. S.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2019, 29 : A130 - A131
  • [2] ATHENA (GOG-3020/ENGOT-ov45): A randomised, double-blind, placebo-controlled, phase 3 study of rucaparib plus nivolumab following front-line platinum-based chemotherapy in ovarian cancer
    Goh, Jeffrey C.
    Baron-Hay, Sally
    Bonaventura, Tony
    Buck, Martin
    Dean, Andrew
    Friedlander, Michael
    Gao, Bo
    Mileshkin, Linda
    Oehler, Martin K.
    Steer, Christopher
    Vi Nguyen
    Goble, Sandra
    Grechko, Nikolay
    Monk, Bradley J.
    Kristeleit, Rebecca S.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2018, 14 : 196 - 196
  • [3] ATHENA (GOG-3020/ENGOT-OV45): A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY OF RUCAPARIB plus NIVOLUMAB FOLLOWING FRONT-LINE PLATINUM-BASED CHEMOTHERAPY IN OVARIAN CANCER
    Monk, B. J.
    Coleman, R. L.
    Fujiwara, K.
    Oza, A. M.
    Westin, S. N.
    O'Malley, D. M.
    Herzog, T. J.
    Marme, F.
    Oaknin, A.
    Eskander, R.
    Lorusso, D.
    Korach, J.
    Lin, K. K.
    Shih, D.
    Goble, S.
    Grechko, N.
    Hume, S.
    Maloney, L.
    McNeish, I.
    Kristeleit, R. S.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2018, 28 : 1019 - 1020
  • [4] ATHENA (GOG-3020/ENGOT-ov45): a randomized, double-blind, placebo-controlled, Phase III study of rucaparib plus nivolumab following front-line platinum-based chemotherapy in ovarian cancer
    Westin, Shannon N.
    Kristeleit, Rebecca S.
    Coleman, Robert L.
    Fujiwara, Keiichi
    Oza, Amit M.
    O'Malley, David M.
    Herzog, Thomas J.
    Marme, Frederik
    Oaknin, Ana
    Eskander, Ramez
    Lorusso, Domenica
    Safra, Tamar
    Korach, Jacob
    Lin, Kevin K.
    Shih, Danny
    Caunt, Lisa
    Goble, Sandra
    Hume, Stephanie
    Maloney, Lara
    McNeish, Iain
    Monk, Bradley J.
    CANCER RESEARCH, 2019, 79 (13)
  • [5] ATHENA (GOG-3020/ENGOT-ov45): a randomized, phase III trial to evaluate rucaparib as monotherapy (ATHENA-MONO) and rucaparib in combination with nivolumab (ATHENA-COMBO) as maintenance treatment following frontline platinum-based chemotherapy in ovarian cancer
    Monk, Bradley J.
    Coleman, Robert L.
    Fujiwara, Keiichi
    Wilson, Michelle K.
    Oza, Amit M.
    Oaknin, Ana
    O'Malley, David M.
    Lorusso, Domenica
    Westin, Shannon N.
    Safra, Tamar
    Herzog, Thomas J.
    Marme, Frederik
    Eskander, Ramez
    Lin, Kevin K.
    Shih, Danny
    Goble, Sandra
    Grechko, Nikolay
    Hume, Stephanie
    Maloney, Lara
    McNeish, Iain A.
    Kristeleit, Rebecca S.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2021, 31 (12) : 1589 - 1594
  • [6] ATHENA-MONO (GOG-3020/ENGOT-ov45): A randomized, double-blind, phase 3 trial evaluating rucaparib monotherapy versus placebo as maintenance treatment following response to first-line platinum-based chemotherapy in ovarian cancer
    Monk, Bradley J.
    Parkinson, Christine
    Lim, Myong Cheol
    O'Malley, David M.
    Oaknin, Ana
    Wilson, Michelle K.
    Coleman, Robert L.
    Lorusso, Domenica
    Oza, Amit M.
    Ghamande, Sharad A.
    Christopoulou, Athina
    Prendergast, Emily
    Demirkiran, Fuat
    Littell, Ramey D.
    Chudecka-Glaz, Anita M.
    Morgan, Mark Aloysuis
    Goble, Sandra M.
    Hume, Stephanie
    Fujiwara, Keiichi
    Kristeleit, Rebecca
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (17)
  • [7] Final safety results from ATHENA-MONO (GOG-3020/ENGOT-ov45), a randomized, placebo-controlled, double-blind, phase 3 trial evaluating rucaparib monotherapy as maintenance treatment in patients with newly diagnosed ovarian cancer
    O'Malley, David M.
    Monk, Bradley J.
    Lim, Myong Cheol
    Pradera, Jose Fuentes
    Buscema, Joseph
    Wilson, Michelle K.
    De Vivo, Rocco
    Herzog, Thomas J.
    Zagouri, Flora
    Oza, Amit M.
    Mikheeva, Olga N.
    Diaz, John Paul
    Lisyanskaya, Alla Sergeevna
    Morris, Robert
    Bruchim, Ilan
    Craib, Marcia
    Connor, Christy
    Shih, Danny
    Fujiwara, Keiichi
    Kristeleit, Rebecca
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [8] Poly-ADP ribose polymerase (PARP) inhibitor regimens for platinum-sensitive ovarian cancer in randomized, double-blind, phase III controlled trials: protocol for a systematic review and network meta-analysis
    Peng, Xiaolian
    Liu, Jie
    FRONTIERS IN MEDICINE, 2025, 12
1